Centessa Pharmaceuticals (NASDAQ: CNTA) is a biotechnology stock that has nearly doubled its value so far this year, and its run may not be over. Analysts at Morgan Stanley have just massively raised their price target for the company. The re-rating from $11 per share to $26 per share is a 136% increase.
Not only that, but it also implies an upside for the company of 66% from its current level. Analysts at B. Riley are even more bullish, putting a price target of $33 on the firm. This…
Read More…
Wake Up to This Biotech Stock That Still Has Big Potential Upside
